Provided are methods of screening for the presence of ovarian carcinoma in a subject. The methods involved contacting a blood, serum, or plasma sample from the subject with an antibody specific for the polypeptide of SEQ ID NO:11. This allows determination of the presence in the biological sample of a molecule that naturally occurs in soluble form, and has an antigenic determinant that is reactive with the antibody. This, in turn, allows detection of the presence of a malignant condition in the subject. The antibody may be a monoclonal antibody, such as a murine monoclonal antibody. Detection of the binding of the antibody to the antigenic determinant may be effected via spectrophotometric detection of a product of an enzyme reaction, for example via enzyme linked immunosorbent assay (ELISA). The subject may have an early stage of ovarian cancer.
